Post-hoc analysis of RCTs and cohorts identifies predictors of remission in ACPA-positive early RA treated with abatacept plus methotrexate or methotrexate alone.
This post-hoc analysis combined data from the AVERT and AVERT-II randomized controlled trials with an observational cohort from the Leiden Early Arthritis Clinic. The study population consisted of ACPA-positive patients with early rheumatoid arthritis, comprising 388 individuals in the methotrexate monotherapy group and 743 in the abatacept plus methotrexate group. The primary outcome assessed was DAS28-CRP remission at 6 and 12 months of follow-up.
At 6 months, DAS28 remission was achieved by 27% of patients in the methotrexate monotherapy group compared to 43% in the abatacept plus methotrexate group. By 12 months, remission rates increased to 39% for the methotrexate group and 53% for the combination therapy group. Additionally, model performance for predicting remission at 6 and 12 months was evaluated using AUROC scores of 0.66 and 0.65 for the methotrexate group, and 0.68 and 0.59 for the abatacept plus methotrexate group, respectively.
Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported in the provided evidence. A key limitation of this analysis is that adding baseline MRI-detected joint inflammation, baseline serology, or HLA-shared epitope alleles did not significantly improve the predictive model performance. Consequently, the study indicates that determining which patients will achieve clinical remission remains challenging.
The practice relevance highlights that while disease activity at presentation and early DAS response are consistent predictors, other biomarkers offer limited additional value. Clinicians should interpret these findings with restraint, recognizing that the evidence is derived from post-hoc analyses of specific trial populations and observational cohorts where causality cannot be definitively established.